[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599164":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":28,"responsibleParty":46,"collaborators":11,"id":48,"slug":11,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":11,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":31,"whyStopped":11,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"5% Minoxidil Foam","EXPERIMENTAL",null,[13],"Drug: 5% minoxidil foam",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo for 5% Minoxidil Foam","PLACEBO_COMPARATOR",[18],"Drug: Placebo for 5% Minoxidil Foam",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","5% minoxidil foam","Trial participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.",[9],{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":11},"Trial participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.",[15],[29],{"facility":30,"status":31,"city":32,"state":11,"zip":11,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Beijing, China","RECRUITING","Beijing","China",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Linyu Zhu","CONTACT","18013840514","zhulinyu@wsh.3sbio.com",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100599164",false,"NCT07080931","Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia","Inclusion Criteria:\n\n* Voluntarily participate in the study and be able to provide a written Informed Consent Form (ICF);\n* Female aged ≥ 18 years;\n* Investigator-diagnosed androgenetic alopecia;\n* Hair loss severity graded D3 to D6 on the Savin scale;\n* Willingness to maintain identical hairstyle, hair color, and hair length at each follow-up visit;\n* No pregnancy plans during the study and for 3 months post-last dose, with commitment to highly effective contraception. Women of childbearing potential must have negative serum pregnancy test ≤7 days prior to first investigational product administration\n\nExclusion Criteria:\n\n* Trial participants with known hypersensitivity to minoxidil or any excipient of the investigational product.\n* Trial participants with known hair loss disorders other than androgenetic alopecia (AGA)\n* Trial participants with any scalp disorder at screening that may interfere with efficacy evaluation, as determined by the investigator.\n* Lactating women\n* Trial participants with history of hypotension or uncontrolled hypertension\n* Trial participants with clinically significant abnormal laboratory findings at screening that may compromise efficacy and safety assessments, as determined by the investigator.\n* Trial participants with clinically significant ECG abnormalities at screening\n* Trial participants with history of malignancy prior to screening.\n* Trial participants known to have conditions or disorders that may affect hair growth or compromise study results.\n* Trial participants with history of using systemically administered therapeutic drugs prior to screening that may interfere with efficacy evaluation, etc.\n* Trial participants with history of topical minoxidil application to alopecia-affected areas prior to screening.\n* Trial participants with no response to prior minoxidil treatment for alopecia\n* Trial participants with history of 5α-reductase inhibitor use prior to screening.\n* Trial participants with history of spironolactone or cyproterone treatment prior to screening.\n* Trial participants with history of autologous platelet-rich plasma (PRP) administration prior to screening.\n* Trial participants with history of chemotherapy, cytotoxic agents, scalp radiation, and\u002For low-level laser therapy (LLLT) or surgical scalp procedures for FAGA prior to screening.\n* Trial participants with history of using medical shampoos or solutions containing ingredients or other components that may interfere with efficacy evaluation prior to screening.\n* Trial participants planning hair transplantation during the study period, or using hair weaving, non-breathable wigs, or hair bonding during treatment.\n* Trial participants in other interventional clinical trials within 3 months before screening (excluding non-interventional studies and screen failures) , or planned concurrent clinical trial enrollment.\n* Trial participants with history of major surgery within 3 months before screening or planning major surgery during the study period.\n* Trial participants deemed by the investigator to have other conditions that may compromise compliance or render them unsuitable for the study.","FEMALE","18 Years",{"count":57,"type":58},294,"ESTIMATED","INTERVENTIONAL",[61],"PHASE3","The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.",[64],"Androgenetic Alopecia",[64],"2026-03-03",{"date":68,"type":69},"2026-03-05","ACTUAL",{"date":71,"type":69},"2025-02-24",{"date":73,"type":58},"2027-12",{"name":5,"class":6},1]